drugset
drugset / Trial / NCT05107336

Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

NCT05107336 ↗

Phase 1 Completed 44 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindOther

Summary

This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy participants

Timeline

Start
2021-11-25
Primary completion
2023-03-21
Completion
2023-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2693 Antisense oligonucleotide — Subcutaneous

Indications

No indication recorded.